SARS-CoV-2 Nsp5 Activates NF-kappa B Pathway by Upregulating SUMOylation of MAVS

The COVID-19 is an infectious disease caused by SARS-CoV-2 infection. A large number of clinical studies found high-level expression of pro-inflammatory cytokines in patients infected with SARS-CoV-2, which fuels the rapid development of the disease. However, the specific molecular mechanism is still unclear. In this study, we found that SARS-CoV-2 Nsp5 can induce the expression of cytokines IL-1 beta, IL-6, TNF-alpha, and IL-2 in Calu-3 and THP1 cells. Further research found that Nsp5 enhances cytokine expression through activating the NF-kappa B signaling pathway. Subsequently, we investigated the upstream effectors of the NF-kappa B signal pathway on Nsp5 overexpression and discovered that Nsp5 increases the protein level of MAVS. Moreover, Nsp5 can promote the SUMOylation of MAVS to increase its stability and lead to increasing levels of MAVS protein, finally triggering activation of NF-kappa B signaling. The knockdown of MAVS and the inhibitor of SUMOylation treatment can attenuate Nsp5-mediated NF-kappa B activation and cytokine induction. We identified a novel role of SARS-CoV-2 Nsp5 to enhance cytokine production by activating the NF-kappa B signaling pathway.

Automated summary

COVID-19 caused by SARS-CoV-2 infection leads to high-level expression of pro-inflammatory cytokines, promoting rapid disease progression. Research found that Nsp5 can enhance cytokine expression by activating the NF-kappa B signaling pathway, with a novel mechanism identified for Nsp5 promoting cytokine production.